Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL49035 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL150929 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL7525209 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL11659 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL18260580 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL2837841 | 1.00 | LMNA (0.43) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL7921264 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL19974227 | 0.94 | SLC34A1 (0.50) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL22263534 | 0.94 | LMNA (0.40) | LMNASLC34A1KDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL22263543 | 0.94 | LMNA (0.40) | LMNASLC34A1KDM4ECYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115785491-A | Method for improving viscosity stability of slow-dissolving methyl cellulose ether | 北方天普纤维素有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-20260092163-A1 | FLAME-RETARDANT COMPOSITION, FLAME-RETARDANT RESIN COMPOSITION, AND MOLDED PRODUCT | ADEKA CORPORATION (JP) | 2026-04-02 | — | — | US | disclosed |
| EP-4632041-A1 | FLAME-RETARDANT COMPOSITION, FLAME-RETARDANT RESIN COMPOSITION AND MOLDED ARTICLE | ADEKA CORPORATION (JP) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024167217-A1 | COMPOSITION FOR CELL OR TISSUE PRESERVATION, AND TOOTH PRESERVATION SOLUTION COMPRISING SAME | 주식회사 현대메디텍 | 2024-08-15 | — | — | WO | disclosed |
| CN-115785491-A | Method for improving viscosity stability of slow-dissolving methyl cellulose ether | 北方天普纤维素有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-111315742-A | Improved process for preparing aminopyrimidine derivatives | 株式会社柳韩洋行 | 2020-06-19 | — | — | CN | disclosed |
| US-7833993-B2 | Immunomodulatory compounds and methods of use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| EP-1439184-B1 | Immunological adjuvant compounds | EISAI R&D MAN CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-7560584-B2 | Immunomodulatory compounds and methods of use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-14 | — | — | US | disclosed |
| EP-2039361-A2 | Use of immunomodulatory compounds | Eisai R&D Management Co., Ltd. (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20030153532-A1 | Immunomodulatory compounds and methods of use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-08-14 | — | — | US | disclosed |
| US-6551600-B2 | A phosphate derivative when co-administered with antigens such as vaccines for bacterial and viral diseases function as immunological adjuvant | EISAI CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| WO-2003011223-A2 | IMMUNOMODULATORY COMPOUNDS AND METHODS OF USE THEREOF | EISAI CO., LTD. (JP) | 2003-02-13 | — | — | WO | disclosed |
| US-20020176861-A1 | Immunological adjuvant compounds compositions and methods of use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1147117-A1 | IMMUNOLOGICAL ADJUVANT COMPOUNDS | Eisai Co., Ltd. (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6290973-B1 | VACCINES FOR BACTERIAL AND VIRAL DISEASES | EISAI CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| WO-2000044758-A1 | IMMUNOLOGICAL ADJUVANT COMPOUND | EISAI CO., LTD. (JP) | 2000-08-03 | — | — | WO | disclosed |
| EP-0088852-B1 | A PROCESS FOR REGENERATING ELECTROLESS PLATING BATH AND A REGENERATING APPARATUS OF ELECTROLESS PLATING BATH | KANTO KASEI CO., LTD. (JP) | 1986-07-30 | — | — | EP | disclosed |
| US-4425205-A | PRECIPITATION COPPER | KANTO KASEI CO., LTD. (JP) | 1984-01-10 | — | — | US | disclosed |
| EP-0088852-A1 | A process for regenerating electroless plating bath and a regenerating apparatus of electroless plating bath | KANTO KASEI CO., LTD. (JP) | 1983-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020176861-A1 | Immunological adjuvant compounds compositions and methods of use thereof | TLR5, MYD88, TLR3 | LMNA 4719/4885SLC34A1 2278/4885KDM4E 4443/4885 |
| US-20260092163-A1 | FLAME-RETARDANT COMPOSITION, FLAME-RETARDANT RESIN COMPOSITION, AND MOLDED PRODUCT | PHOSPHO1, PAF1, PPA1 | LMNA 2518/4885SLC34A1 704/4885KDM4E 1566/4885 |
| US-20030153532-A1 | Immunomodulatory compounds and methods of use thereof | TLR5, TLR3, TLR6 | LMNA 4854/4885SLC34A1 2208/4885KDM4E 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.